NCT03509142View on ClinicalTrials.gov

A First-in-Man Study of IBS

NACompletedINTERVENTIONAL
Enrollment

45

Participants

Timeline

Start Date

April 10, 2018

Primary Completion Date

July 19, 2019

Study Completion Date

December 10, 2023

Conditions
Single Coronary Vessel Disease
Interventions
DEVICE

Sirolimus-eluting Iron Bioresorbable Coronary Scaffold System

Implantation of Sirolimus-eluting Iron Bioresorbable Coronary Scaffold System (IBS)

Trial Locations (1)

100037

Beijing Fuwai hospital, Beijing

All Listed Sponsors
lead

Lifetech Scientific (Shenzhen) Co., Ltd.

INDUSTRY

NCT03509142 - A First-in-Man Study of IBS | Biotech Hunter | Biotech Hunter